On 19 Nov 2025, Novelix Pharmaceuticals, a key player in the Retailing sector, recorded this fresh peak price, underscoring the stock’s strong upward trajectory. The stock has been on a consistent rise, registering gains for six consecutive trading days, culminating in a cumulative return of 22.1% during this period. This rally has outpaced the sector’s performance, with Novelix Pharmaceuticals outperforming its Retailing peers by 0.64% on the day of the new high.
Examining the technical indicators, the stock is trading above all major moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This alignment suggests a robust momentum underpinning the price action, reflecting sustained investor confidence in the stock’s current valuation levels.
Only 1% make it here. This Large Cap from the Gems, Jewellery And Watches sector passed our rigorous filters with flying colors. Be among the first few to spot this gem!
- Highest rated stock selection
- Multi-parameter screening cleared
- Large Cap quality pick
From a broader market perspective, the Sensex opened flat on the same day, with a marginal decline of 29.24 points but later edged up to trade at 84,681.47, reflecting a 0.01% gain. The benchmark index remains close to its own 52-week high of 85,290.06, currently about 0.72% away from that peak. The Sensex’s position above its 50-day moving average, which itself is above the 200-day moving average, indicates a generally bullish market environment that may have supported the positive momentum in stocks like Novelix Pharmaceuticals.
Mid-cap stocks have been leading the market gains, with the BSE Mid Cap index registering a 0.09% increase on the day. While Novelix Pharmaceuticals is classified within the Retailing sector, its market capitalisation grade stands at 4, reflecting a mid-sized market cap status. The company’s Mojo Score is 50.0, with a current Mojo Grade of Hold, following an adjustment in evaluation from a previous Sell grade on 14 Nov 2025. This revision coincides closely with the stock’s recent price movements and the trigger event of reaching the 52-week high on 19 Nov 2025.
Novelix Pharmaceuticals or something better? Our SwitchER feature analyzes this micro-cap Retailing stock and recommends superior alternatives based on fundamentals, momentum, and value!
- SwitchER analysis complete
- Superior alternatives found
- Multi-parameter evaluation
Looking at the stock’s annual performance, Novelix Pharmaceuticals has delivered a substantial return of 202.30% over the past year, significantly outpacing the Sensex’s 9.18% gain during the same timeframe. This stark contrast highlights the stock’s exceptional growth relative to the broader market benchmark. The 52-week low for the stock was Rs.23, indicating a wide trading range and considerable appreciation over the last twelve months.
On the day Novelix Pharmaceuticals hit its new 52-week high, the stock recorded a day change of 4.06%, reinforcing the strength of the rally. This price movement reflects the stock’s ability to maintain upward momentum even as it approaches historically high valuation levels. The company operates within the Retailing industry, a sector that has shown resilience and selective strength in the current market cycle.
In summary, Novelix Pharmaceuticals’ attainment of a new 52-week high at Rs.70.16 marks a significant achievement, supported by a series of consecutive gains and favourable technical indicators. The stock’s performance over the past year, combined with its recent momentum, positions it as a noteworthy example of strong price appreciation within the Retailing sector.
Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
